Evidence map›Paper›PMID 35458232›Full record

ArticleNutrients2022

Tzu-Shao Yeh, Tze-Huan Lei, Jen-Fang Liu, Mei-Chich Hsu

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Novel metabolic and lipidomic biomarkers of sarcopenia.Journal of cachexia, sarcopenia and muscle · 2024
    Article
  9. Annals of medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Tzu-Shao YehSchool of Public Health, Nantong University, Nantong 226019, China.ORCID 0000-0001-5684-5932
Tze-Huan LeiCollege of Physical Education, Hubei Normal University, Huangshi 435002, China.ORCID 0000-0003-3157-099X
Jen-Fang LiuDepartment of Nutrition and Health Sciences, Chang Gung University of Science and Technology, Taoyuan 33303, Taiwan.
Mei-Chich HsuDepartment of Sports Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Chang Gung University of Science and Technology · TWHubei Normal University · CNKaohsiung Medical University · TWNantong University · CN

Funding

Taiwan National Science Council NSC 99-2410-H-179-006-MY2.
6 · The paper itself

Abstract

Astragalus membranaceus (AM) is classified as a high-class traditional herbal medicine, which has strengthened vitality and multifunctional pharmacological activities, but limited empirical evidence is available to support its effects in muscular hypertrophy. It evokes skeletal muscle hypertrophy by increasing anabolic pathway, which is essential to prevent sarcopenia in elderly population. In this study, we examined the effects of AM on skeletal muscle hypertrophy by focusing on the molecular mechanism. We employed an in vitro model to investigate whether AM-treated skeletal muscle, as represented by myotube C2C12 cells, was hypertrophic, and to further investigate the efficacy of AM-activated phosphorylation of PI3K/Akt/mTOR signaling that must occur prior to myotube hypertrophy. The results showed that the myotubes formed larger multinucleated myotubes with increased diameter and thickness (1.16-fold relative to control group, p < 0.05). Administration of PI3K and mTOR inhibitors abolished AM-induced muscular hypertrophy. Moreover, AM-induced PI3K-mediated myotube hypertrophy was accompanied by the activation of Akt and mTOR signaling. We concluded that the AM is a nutritional activator to enhance muscular hypertrophy by increasing PI3K/Akt/mTOR signaling phosphorylation. As the AM is effective in myotube hypertrophy, AM and its derivatives may be promising candidates for ergogenic aid to prevent sarcopenia.

Indexed as

Astragalus propinquusPhosphatidylinositol 3-KinasesSarcopeniaTOR Serine-Threonine KinasesAgedHumansHypertrophyMuscle Fibers, SkeletalPhosphorylationProto-Oncogene Proteins c-aktMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesgeriatricsHuangqimTORsarcopeniatraditional Chinese medicine

Identifiers

PMID35458232
PMCPMC9028211
OpenAlexW4224270495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.